health
A 52-week semaglutide trial examines kidney effects in diabetes
In the 52-week REMODEL trial, semaglutide was associated with changes in kidney vascular measures and tissue signals in people with type 2 diabetes and chronic kidney disease. The three coprimary MRI outcomes did not differ significantly from placebo.